Subjects must give a written, signed and dated informed consent

Chronic plaque-type psoriasis present for at least 6 months before randomization

Moderate to severe plaque psoriasis as defined at randomization by:

* PASI score of ≥12 and

* Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% and

* IGA mod 2011 ≥3 (based on a scale of 0-4)

Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:

* Topical treatment (including topical corticosteroids) and/or

* Phototherapy and/or

* Previous systemic therapy

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis